Indication

Systemic-onset juvenile idiopathic arthritis

Systemic-onset juvenile idiopathic arthritis is a severe, rare subtype of juvenile idiopathic arthritis that primarily affects children younger than 16 years of age. Read more about Systemic-onset juvenile idiopathic arthritis

12 drugs 8 manufacturers

Advertisement

Drugs that treat it

Common Systemic-onset juvenile idiopathic arthritis therapies.

Showing 10–12 of 12 drugs

ILARIS (canakinumab/PF)

ANTI-INFLAMMATORY - INTERLEUKIN 1 RECEPTOR ANTAGONIST·ACUTE GOUTY ARTHRITIS·+7
Novartis Pharmaceuticals
Filter & compare in the drug finder →Opens the drug finder with Systemic-onset juvenile idiopathic arthritis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Systemic-onset juvenile idiopathic arthritis.

Systemic-onset juvenile idiopathic arthritis is a severe, rare subtype of juvenile idiopathic arthritis that primarily affects children younger than 16 years of age.

Pathophysiologically categorized as an autoinflammatory disorder rather than a classical autoimmune disease, it is driven by dysregulated innate immune pathways and high levels of pro-inflammatory cytokines, notably interleukin-1 and interleukin-6.

Clinically, it is characterized by chronic or recurring arthritis accompanied by prominent systemic manifestations, including quotidian high-spiking fevers, an evanescent salmon-pink maculopapular rash, generalized lymphadenopathy, hepatosplenomegaly, and serositis.

Patients are also at heightened risk for life-threatening complications, most notably macrophage activation syndrome.

Personalize your experience

Follow Systemic-onset juvenile idiopathic arthritis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it